A healthcare company trying to launch a new headache curing drug. Should or shouldn't they invest when they already have a general painkiller in the market
Zurück zur Übersicht
20
How would I approach this? Possible Framework?
2
4,6k
Schreibe die erste Antwort!
Bisher hat niemand auf diese Frage reagiert.
Beste Antwort
Vlad
bearbeitet am 5. Juni 2018
Coach
McKinsey / Accenture Alum / Got all BIG3 offers / Harvard Business School
Hi,
Hi,
I recommend starting with clarifying the objective - Which metrics you need to achieve with the product? Most probably it will be ROI.
I would also clarify whether it's our painkiller on the market or the product of the competitors since competition and cannibalization are the two different cases. Then I will follow up with the structure:
Analyze our product:
- The value proposition of a product compared to the painkiller
- Different use cases of a product compared to the painkiller
- Unit economics (Current unit costs and costs in relation to scale, Investments, ROI targets, Competitor / substitutes pricing)
- Key capabilities to compete (Patent, distribution, etc)
Analyze the market:
- Size and growth rates of the painkiller market
- Size and growth rate of headache drugs
- Regulation - are they both OTC? Prescribed? Is it different by geography?
Analyze the competitors:
- Market shares, growth rates, profits
- Product (Value proposition)
- Unit economics (Value proposition vs. price vs. costs)
- Key capabilities (Distribution, supply, assets, knowledge, etc)
investment decision:
- Costs, benefits, and investments
- ROI
- Risks
Best!
0 Kommentare
Sidi
am 5. Juni 2018
Coach
McKinsey Senior EM & BCG Consultant | Interviewer at McK & BCG for 7 years | Coached 500+ candidates secure MBB offers
Hi Anonymous,
the new drug should be launched if the net value associated with this move exceeds the investment cost over the client's target investment horizon. Morover, Risk needs to be manageable.
So you have 4 buckets to investigate:
- Net value (expected profits of new drug + impact on profits of current painkiller (potential cannibalization!))
- Investment Horizon
- Investment need for launch of the new drug
- Wider risks associated with the new drug (regulation? competitive responses? consumer sentiment?...)
Cheers, Sidi
Jetzt kostenlos anmelden, um alle Antworten zu lesen.
Jetzt kostenlos anmelden, um alle Antworten zu lesen.
Ähnliche Fragen
Beliebteste Beiträge
I am expecting interviews at Oliver Wyman for the DACH offices. What type of cases should be my focus and how does the process look like?
12
am 22. Juli 2026
DACH
5
100+
Beste Antwort von
Elvira
Coach
Senior Manager zeb Consulting | Case Interview & Personal Fit Coach | CV Review | Banking & Consulting
5 Antworten
100+ Aufrufe
+2
Applied to McKinsey ME office, status is "under review" but no Solve invite yet, is this normal?
12
am 22. Juli 2026
Naher Osten
5
100+
Beste Antwort von
Federico
Coach
Ex-BCG Partner | Interviewer and Career Advisor | Fully tailored approach
5 Antworten
100+ Aufrufe
+2
Rejected by Bain without a test?
12
am 24. Juli 2026
Global
6
100+
Beste Antwort von
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
6 Antworten
100+ Aufrufe
+3
Pivoting from big tech to consulting
12
am 24. Juli 2026
Naher Osten
7
100+
Beste Antwort von
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
7 Antworten
100+ Aufrufe
+4
Issue Tree vs. Action Plan in Case Interview Structure
15
am 25. Juli 2026
Global
7
100+
Beste Antwort von
Alessandro
Coach
McKinsey Senior Engagement Manager | Interviewer Lead | 1,000+ real MBB interviews | 2026 Solve, PEI, AI-case specialist
7 Antworten
100+ Aufrufe
+4